Current Issue

Sponsored
Keywords

Orphan Drugs - Related Content

Wall Street BioBeat: The New Economics of Orphan Diseases
Opportunities Abound in Rare Disease Space as Market Is Projected to Continue Growing
Feature Articles: Orphan Drug Changes Brewing at the FDA
Initiatives to De-Risk Drug Development Could Include Redesigning Clinical Trial Requirement
BioMarket Trends: Big Pharma Steps Into Orphan Drug Market
Main Attraction of Sector Is the Availability of a Market Space Devoid of Competition
Wall Street BioBeat: Big Pharma Reassesses Orphan Drug Sector
Drug Firms Are Aggressively Seeking Replacements for Dwindling Blockbusters
Corporate Profiles: Firm Aims to Regulate RNA in Rare Diseases
PTC Therapeutics Focuses on Small Molecule Drugs for Genetic Disorders and Cancer

Despite Flat Budget, NIH’s TRND Program Tries to Spark Interest in Rare and Neglected Diseases
January 31, 2012
With 14 approved programs in total, TRND has progressed two into clinical development.
While Advocacy Abounds, Orphan Drug Development Success Remains Elusive
June 6, 2011
Questions persist about whether legislature can translate ongoing research into medications.
Changes Brewing at the FDA for Orphan Drugs
September 13, 2010
Initiatives to de-risk drug development could include redesigning clinical trial requirements.
Big Pharma Adopting Orphan Drug Strategy
December 14, 2009
Potential for profitability in small markets is beginning to lure companies away from the failing blockbluster model.

GRANDRx—Mission, Goals, and Challenges
Interview with Patrick Terry, Acting CEO of the Grand Therapeutics Foundation, and Christopher Austin, M.D., Director of the NIH Chemical Genomics Center, and Member, Editorial Board, ASSAY and Drug Development Technologies.